Screening for a fungicidal candidate effective against multidrug-resistant fungi, such as Candida auris, is being conducted through government-funded R&D projects.
Recently research has commenced on dermatophyte infections, which have become a concern in India following the COVID-19 pandemic.
ATB1606
Anti-Inflammatory Agents
Atopic Dermatitis / Inflammatory Bowel Disease
It is an immune-related anti-inflammatory agent that regulates the interaction between TSLP and TSLPR, which are associated with the Th2 immune response, and is a potential best-in-class drug candidate.
The global market size for the developing applications exceeds 50 trillion won.
As a non-steroidal small-molecule synthetic drug, it has potential for expansion into various inflammatory and immune-related indications.
The atopic dermatitis treatment is in the preclinical stage (IND enabling) for clinical trial approval and is expected to progress to clinical trials.
SAMH
Biocompatible Materials
Next-Generation Dermal Fillers / Wound Dressings
A hyaluronic acid-based self-crosslinking injectable drug delivery platform.
The global market size for the developing applications exceeds 50 trillion won.
Based on its biocompatible material properties, it allows for diverse drug delivery routes and can be expanded into various medical devices or applications.
Application areas: Next-generation dermal fillers, injectable sustained-release drug delivery platforms, microneedle patch materials, wound dressings, etc.
The GMP production facility was completed in 2021 and received GMP manufacturing certification from the MFDS in 2023.
Domestic clinical trials are planned for the future.
